GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Artiva Biotherapeutics ARTV · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.83

+1.59%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Artiva Biotherapeutics — daily ARTV Delayed
Market value
$94.0m
Last close × shares
Volume
773.2k
Shares, 19 Nov 2026

About Artiva Biotherapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Artiva Biotherapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ARTV. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $83.9m. At that date it held total assets of $130.9m and shareholders' equity of $110.0m.

In its own words

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured and stored frozen and ready to ship to a patient’s treatment location, making them what we believe to be “off-the-shelf.” Our lead product candidate, AlloNK (also known as AB-101), is an allogeneic, non-genetically modified, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies (mAbs) to drive B-cell depletion. We are currently evaluating AlloNK in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis (RA) and Sjögren’s disease (SjD). We are prioritizing refractory RA as our lead indication for AlloNK development. We expect to share initial clinical response data across dose levels from more than 15 refractory RA patients, several of whom will have 6 months or more follow up, in the first half of 2026. In addition, we plan to conduct FDA regulatory interactions in the first half of 2026 to align on the pivotal trial design for AlloNK in refractory RA.

Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗

More about Artiva Biotherapeutics →

Latest on Artiva Biotherapeutics

Our reporting

Next results

9 Mar 2027

Due on 9 Mar 2027. Analysts expect earnings of -0.56 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Artiva Biotherapeutics's ticker?

Artiva Biotherapeutics trades as ARTV on its US listing, under ISIN US04317A1079.

What was Artiva Biotherapeutics's last closing price?

3.83 on 19 Nov 2026. The figure is in USD and is never converted.

When does Artiva Biotherapeutics next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.